Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 1.00 |
| ▸ | NAALAD2 | Q9Y3Q0 | 8/20 | 1.00 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14102890 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18161468 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14102870 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL12145776 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14729426 | 0.94 | FOLH1 (0.88) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14102995 | 0.92 | FOLH1 (0.84) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL11936625 | 0.90 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL21321511 | 0.90 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18637007 | 0.90 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL20841451 | 0.90 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676472-A2 | BI-SPECIFIC ADAPTERS AND THEIR USE WITH UNIVERSAL CAR-T CELLS IN THE TREATMENT OF TUMORS AND THE INHIBITION OF CANCER-ASSOCIATED FIBROBLASTS | Purdue Research Foundation (US) | 2026-01-14 | — | — | EP | claimed |
| WO-2025245374-A1 | PEPTIDIC CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELL ADAPTERS AND USES THEREOF | THE NEMOURS FOUNDATION (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250222143-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-07-10 | — | — | US | claimed |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-06-26 | — | — | US | claimed |
| US-20250082794-A1 | ANTIMONY CHELATES FOR TARGETED AUGER THERAPY AND IMAGING DIAGNOSTICS | U. S. DEPARTMENT OF ENERGY | 2025-03-13 | — | — | US | claimed |
| CN-110730908-B | Engineered cells expressing Prostate Specific Membrane Antigen (PSMA) or modified versions thereof and related methods | 朱诺治疗学股份有限公司 | 2025-01-21 | — | — | CN | claimed |
| WO-2024191886-A9 | BI-SPECIFIC ADAPTERS AND THEIR USE WITH UNIVERSAL CAR-T CELLS IN THE TREATMENT OF TUMORS AND THE INHIBITION OF CANCER-ASSOCIATED FIBROBLASTS | PURDUE RESEARCH FOUNDATION (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240390505-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR REJUVENATION OF CAR T-CELLS | PURDUE RESEARCH FOUNDATION | 2024-11-28 | — | — | US | claimed |
| WO-2024191886-A2 | BI-SPECIFIC ADAPTERS AND THEIR USE WITH UNIVERSAL CAR-T CELLS IN THE TREATMENT OF TUMORS AND THE INHIBITION OF CANCER-ASSOCIATED FIBROBLASTS | PURDUE RESEARCH FOUNDATION (US) | 2024-09-19 | — | — | WO | claimed |
| WO-2024145593-A1 | RECOMBINANT RETROVIRUS, COMPOSITIONS, AND METHODS OF USE | KELONIA THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| US-20170281801-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | On Target Laboratories, Inc. | 2017-10-05 | — | — | US | claimed |
| WO-2017044584-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | On Target Laboratories, LLC (US) | 2017-03-16 | — | — | WO | claimed |
| US-20170066719-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | On Target Laboratories, Inc. | 2017-03-09 | — | — | US | claimed |
| US-20170065729-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | On Target Laboratories, Inc. | 2017-03-09 | — | — | US | claimed |
| WO-2016205410-A2 | DEFINED MULTI-CONJUGATE OLIGONUCLEOTIDES | MPEG LA, LLC (US) | 2016-12-22 | — | — | WO | claimed |
| US-20160367685-A1 | DUPA-INDENOISOQUINOLINE CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | claimed |
| EP-3057991-A1 | CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF | The California Institute for Biomedical Research (US) | 2016-08-24 | — | — | EP | claimed |
| WO-2015069766-A1 | DUPA-INDENOISOQUINOLINE CONJUGATES | PURDUE RESEARCH FOUNDATION (US) | 2015-05-14 | — | — | WO | claimed |
| WO-2015057852-A1 | CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-04-23 | — | — | WO | claimed |
| WO-2013181597-A2 | THIOL-ENE CLICK CHEMISTRY FOR DRUG CONJUGATES | SYNCHEM, INC. (US) | 2013-12-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281801-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | KLK3, FOLH1, CD47 | FOLH1 2/4885NAALAD2 79/4885RIMKLA 692/4885 |
| US-20250222143-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | PAICS, RABGGTB, PARP1 | FOLH1 138/4885NAALAD2 1304/4885RIMKLA 1887/4885 |
| US-20160367685-A1 | DUPA-INDENOISOQUINOLINE CONJUGATES | PDS5B, KLK3, PDS5A | FOLH1 340/4885NAALAD2 295/4885RIMKLA 2256/4885 |
| US-20170066719-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | KLK3, FOLH1, CD47 | FOLH1 2/4885NAALAD2 79/4885RIMKLA 692/4885 |
| US-20170065729-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | KLK3, FOLH1, CD47 | FOLH1 2/4885NAALAD2 79/4885RIMKLA 692/4885 |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | QPCT, SSTR5, SSTR4 | FOLH1 30/4885NAALAD2 1477/4885RIMKLA 481/4885 |
| US-20250082794-A1 | ANTIMONY CHELATES FOR TARGETED AUGER THERAPY AND IMAGING DIAGNOSTICS | SOD1, SOD3, ABCB7 | FOLH1 89/4885NAALAD2 3949/4885RIMKLA 3017/4885 |
| US-20240390505-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR REJUVENATION OF CAR T-CELLS | CD47, ICOS, PBK | FOLH1 1256/4885NAALAD2 1868/4885RIMKLA 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.